Tango Targeted Combination Therapy Yields 82 Percent Tumor Response in Advanced Pancreatic Cancer

When treating advanced pancreatic cancer, oncologists typically rely on broad-spectrum chemotherapy regimens that attack all rapidly dividing cells. A newly tested oral drug combination departs from that standard by targeting two specific genetic vulnerabilities at once, shrinking tumors in more than 80 percent of trial participants without using traditional chemotherapy.[1][7]

The data, presented at the European Society for Medical Oncology (ESMO) congress in Madrid, tracks an experimental regimen developed by Tango Therapeutics and Revolution Medicines. The Phase 1/2 trial evaluated the combination in patients with metastatic pancreatic ductal adenocarcinoma whose tumors had already progressed after initial treatments.[4][6]

While the results represent an early snapshot from a small group of patients, the response rate is unusually high for a disease that notoriously resists targeted therapies. The findings provide enough clinical evidence to move the combination into a large, randomized trial for newly diagnosed patients next year.[5][8]

Targeting a dual vulnerability

The experimental regimen is designed specifically for tumors that carry two distinct genetic signatures: a mutation in the RAS gene family and a deletion of the MTAP gene. These dual markers appear together in a significant subset of pancreatic cancers, creating a specific biological profile that the drugs exploit.[4][5]

Daraxonrasib, developed by Revolution Medicines, is engineered to inhibit active forms of RAS proteins. Mutated RAS acts as an internal engine that drives uncontrolled cancer growth, and blocking it has been a long-standing goal in oncology that researchers have only recently begun to achieve.[1][6]

The second drug in the regimen, Tango Therapeutics’ vopimetostat, targets the MTAP deletion. When a tumor loses the MTAP gene, its cells undergo a metabolic shift that makes them highly dependent on a specific enzyme called PRMT5 to survive, process RNA, and maintain their basic cellular functions.[5][7]

Vopimetostat inhibits PRMT5, effectively starving the cancer cells of an enzyme they desperately need, while sparing healthy cells that retain their normal MTAP function. By combining the two drugs, researchers aim to suppress the primary growth signal while simultaneously exploiting the tumor's secondary structural weakness.[4][6]

The clinical trial results

In the updated trial data, 22 patients with the required genetic profile were evaluated for efficacy. Eighteen of those participants, or 82 percent, experienced tumor shrinkage significant enough to meet the study’s definition of an objective response.[3][8]

Every patient in the evaluable group saw their disease controlled, meaning their tumors either shrank or stopped growing. Furthermore, 88 percent of the participants remained progression-free at the nine-month mark, and the median time before the disease worsened had not yet been reached by the August data cutoff.[2][4]

These figures update an earlier, smaller dataset released in June, which showed a 92 percent response rate among just 12 patients. While the percentage dropped slightly as the trial expanded, an 82 percent response rate remains one of the most compelling signals reported in pancreatic cancer research this year.[5][7]

"It is encouraging to see that the clinical activity and tolerability observed in our initial June 2026 dataset has been confirmed with longer follow-up and in a larger patient population," said Malte Peters, chief executive officer of Tango Therapeutics.[4]

Safety and tolerability are critical hurdles for any new combination therapy, as pairing two active drugs often compounds their individual side effects. At the 200-milligram dose of vopimetostat, the combination was generally well-tolerated, with investigators reporting no dose-limiting toxicities and no patients discontinuing treatment due to adverse events.[4][8]

Moving to front-line testing

However, researchers noted that a higher 250-milligram dose proved difficult for patients to tolerate, resulting in dose-limiting toxicities like severe rash and stomatitis. Consequently, the lower dose will serve as the standard moving forward as the companies prepare for broader testing.[6][7]

Armed with these results, Tango Therapeutics plans to initiate a global Phase 3 clinical trial in the first half of 2027. Unlike the current study, which enrolled patients who had already exhausted other options, the upcoming trial will test the combination as a front-line treatment for newly diagnosed patients.[4][8]

The Phase 3 trial will randomize participants to receive either the experimental oral combination or the current standard-of-care chemotherapy. This head-to-head comparison is the definitive test required by regulators to prove whether the targeted approach actually extends lives better than existing treatments.[5][6]

If the Phase 3 trial proves successful, the regimen would offer a chemotherapy-free option for a substantial portion of pancreatic cancer patients. Because standard chemotherapy often brings severe systemic side effects that limit how long patients can endure treatment, an oral targeted therapy could meaningfully improve daily quality of life.[1][7]

What this means for patients now

For patients currently navigating a pancreatic cancer diagnosis, the immediate takeaway is the importance of comprehensive biomarker testing. Because this therapy only works against tumors with specific MTAP and RAS mutations, patients must have their tumor genetics profiled to know if they might eventually qualify.[5][8]

The medicines remain strictly investigational and are not available outside of clinical trials. The 22-patient dataset, while promising, is not large enough to establish a definitive survival benefit or to guarantee that the safety profile will hold up across a wider population.[5][8]

Other pharmaceutical companies, including Bristol Myers Squibb and Amgen, are also developing PRMT5 inhibitors for MTAP-deleted tumors, signaling broad industry confidence in the biological target. As these competing trials progress, patients with this specific genetic profile may see multiple targeted options emerge in the coming years.[2][7]

The trial also included a small cohort of patients with non-small cell lung cancer carrying the same genetic markers. Among the five evaluable lung cancer patients, four achieved a confirmed partial response, suggesting the dual-targeting strategy may work across different tumor types sharing the MTAP deletion.[6][7]

Despite the strong clinical data, Tango Therapeutics saw its stock price decline by more than 15 percent following the ESMO presentation. Financial analysts attributed the drop to investors taking profits after a significant run-up ahead of the conference, as well as the slight decrease from the earlier 92 percent response rate.[3][8]

The true test of the vopimetostat and daraxonrasib combination will arrive when the Phase 3 trial begins enrolling thousands of patients next year. Until those randomized results are published, oncologists will watch closely to see if the durability of these early responses persists as the current trial participants are followed for longer periods.[5][6]